Regenxbio Stock Price, News & Analysis

REGENXBIO announced positive interim data from the Phase II ALTITUDE trial of RGX-314, a gene therapy for diabetic retinopathy (DR). In Cohort 1, 33% of patients showed a two-step improvement in DR severity after three months, compared to none in the control group. The treatment was well-tolerated with no serious drug-related adverse events. Cohorts 2 and 3 are ongoing at a higher dose of 5x10¹¹ GC/eye. This therapy could significantly benefit the approximately eight million people affected by DR in the U.S.

REGENXBIO (Nasdaq: RGNX) announced positive initial data from the Phase II AAVIATE trial of RGX-314 for wet AMD treatment via suprachoroidal delivery. In Cohort 1, 14 patients showed stable visual acuity and retinal thickness at six months, with a 75.9% reduction in anti-VEGF injections. No drug-related serious adverse events were reported among 50 patients in Cohorts 1-3. The trial is expanding to include a third dose level of RGX-314. A conference call featuring key opinion leaders will provide further insights.

REGENXBIO announced that data from its RGX-314 clinical trials will be presented at the American Society of Retina Specialists Annual Meeting in San Antonio, TX, from October 8-12, 2021. The presentations will focus on interim results from the Phase II ALTITUDE trial, which evaluates RGX-314 for diabetic retinopathy. Key presentations include early results from Cohort 1 on October 9 and additional studies on neovascular AMD on October 11.

REGENXBIO Inc. (Nasdaq: RGNX) announced the presentation of interim data for the RGX-314 Phase II trial targeting wet age-related macular degeneration (AMD) at the Retina Society 54th Annual Scientific Meeting from September 29 to October 2, 2021. The data from Cohort 1 will be discussed during two oral presentations on October 1, featuring experts in ophthalmology. This investigational gene therapy aims for a one-time treatment to inhibit VEGF and reduce fluid accumulation in the retina. A conference call is scheduled for the same day to review the findings.

AbbVie and REGENXBIO announced a partnership to develop RGX-314, a gene therapy for wet age-related macular degeneration (AMD) and diabetic retinopathy (DR). REGENXBIO will complete ongoing trials, while AbbVie leads global development and commercialization. AbbVie will pay REGENXBIO $370 million upfront, with potential total payments of up to $1.38 billion based on milestones. They will share profits from U.S. sales equally, with AbbVie paying tiered royalties internationally. The deal is expected to close by the end of 2021, contingent on regulatory approvals.

REGENXBIO Inc. (Nasdaq: RGNX) announced its participation in upcoming virtual investor conferences. Key events include a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 14, 2021, and another at Chardan's 5th Annual Genetic Medicines Conference on October 5, 2021. Webcasts for these chats will be available on the company's website for 90 days post-event. REGENXBIO specializes in gene therapy utilizing its proprietary NAV Technology Platform, which includes over 100 AAV vectors aimed at various therapeutic applications.

REGENXBIO Inc. (Nasdaq: RGNX) has appointed Dr. Jean Bennett and Mr. George Migausky to its Board of Directors, effective September 3, 2021. Dr. Bennett is known for her expertise in gene therapy and has contributed significantly to the field, including the development of Luxturna®. Mr. Migausky brings over 30 years of financial and operational leadership experience. The appointments come as REGENXBIO advances its clinical programs, particularly RGX-314 for wet age-related macular degeneration. The company also announced the resignation of Luke M. Beshar from the board.

REGENXBIO (RGNX) reported $22 million in Q2 2021 revenue, up from $16.6 million in Q2 2020, driven by a $6.5 million increase in Zolgensma royalties. The company holds $593 million in cash as of June 30, 2021, positioning it well to fund operations through mid-2023. Ongoing clinical trials for RGX-314 and RGX-121 show promise, with interim data set for presentation at the Retina Society meeting. Meanwhile, the net loss rose to $57.6 million, reflecting increased R&D and G&A expenses. The firm aims to submit an IND for RGX-202 by year-end 2021.

REGENXBIO Inc. (Nasdaq: RGNX) will host a conference call on August 9, 2021, at 4:30 p.m. ET to discuss its Q2 2021 financial results and operational highlights. Interested participants can join the call by dialing (855) 422-8964 or accessing the webcast on the company's website. REGENXBIO focuses on gene therapy using its proprietary NAV^® Technology Platform, which includes over 100 adeno-associated viral vectors. The company aims to develop a robust pipeline across various therapeutic areas.